Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q198728> ?p ?o }
Showing triples 1 to 48 of
48
with 100 triples per page.
- Q198728 subject Q11123155.
- Q198728 subject Q52319.
- Q198728 subject Q7334142.
- Q198728 subject Q9052323.
- Q198728 abstract "Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.Oncologists have complained, however, that many patients cannot afford the "astronomical" cost of $138,000 a year, which makes it one of the most expensive drugs in medicine, and far more expensive than what is needed to pay the development costs.The United States Food and Drug Administration approved the drug as a candidate in 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.".
- Q198728 atcPrefix "L01".
- Q198728 atcSuffix "XE24".
- Q198728 casNumber "943319-70-8".
- Q198728 chEBI "78543".
- Q198728 fdaUniiCode "4340891KFS".
- Q198728 iupacName "3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide".
- Q198728 pubchem "24826799".
- Q198728 thumbnail Ponatinib2DACS.svg?width=300.
- Q198728 wikiPageWikiLink Q11123155.
- Q198728 wikiPageWikiLink Q1129111.
- Q198728 wikiPageWikiLink Q17005771.
- Q198728 wikiPageWikiLink Q177094.
- Q198728 wikiPageWikiLink Q180664.
- Q198728 wikiPageWikiLink Q188261.
- Q198728 wikiPageWikiLink Q204711.
- Q198728 wikiPageWikiLink Q3425168.
- Q198728 wikiPageWikiLink Q412327.
- Q198728 wikiPageWikiLink Q419940.
- Q198728 wikiPageWikiLink Q4653724.
- Q198728 wikiPageWikiLink Q466892.
- Q198728 wikiPageWikiLink Q4875411.
- Q198728 wikiPageWikiLink Q5031405.
- Q198728 wikiPageWikiLink Q52319.
- Q198728 wikiPageWikiLink Q7199670.
- Q198728 wikiPageWikiLink Q729735.
- Q198728 wikiPageWikiLink Q7334142.
- Q198728 wikiPageWikiLink Q9052323.
- Q198728 wikiPageWikiLink Q906415.
- Q198728 atcPrefix "L01".
- Q198728 atcSuffix "XE24".
- Q198728 casNumber "943319".
- Q198728 chebi "78543".
- Q198728 iupacName "3".
- Q198728 pubchem "24826799".
- Q198728 unii "4340891".
- Q198728 type ChemicalSubstance.
- Q198728 type Drug.
- Q198728 type ChemicalObject.
- Q198728 type Thing.
- Q198728 type Q8386.
- Q198728 comment "Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib.".
- Q198728 label "Ponatinib".
- Q198728 depiction Ponatinib2DACS.svg.